<div id="readability-page-1"><p><span>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report)</span> had its price objective increased by analysts at Deutsche Bank Aktiengesellschaft  from $110.00 to $111.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a &#34;hold&#34; rating on the stock. Deutsche Bank Aktiengesellschaft's target price suggests a potential upside of 14.38% from the company's current price.</p><div><p><span></span><span>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</span></p></div><ul><li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li></ul><p>MRK has been the topic of a number of other research reports. Citigroup initiated coverage on Merck &amp; Co., Inc. in a research report on Monday, October 13th. They issued a &#34;neutral&#34; rating and a $95.00 price objective on the stock. Wells Fargo &amp; Company lowered their price target on Merck &amp; Co., Inc. from $97.00 to $90.00 and set an &#34;equal weight&#34; rating on the stock in a report on Wednesday, July 30th. Weiss Ratings  reissued a &#34;hold (c-)&#34; rating on shares of Merck &amp; Co., Inc. in a report on Wednesday, October 8th. Berenberg Bank lowered shares of Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and decreased their price target for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Finally, Scotiabank assumed coverage on shares of Merck &amp; Co., Inc. in a research report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $105.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, ten have given a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, Merck &amp; Co., Inc. presently has a consensus rating of &#34;Hold&#34; and an average target price of $104.88.</p><p><b>Get Our Latest Research Report on MRK</b></p><h2>Merck &amp; Co., Inc. Stock Performance</h2><ul><li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li></ul><p>NYSE:MRK traded up $4.19 during trading hours on Tuesday, reaching $97.05. The stock had a trading volume of 19,419,445 shares, compared to its average volume of 14,566,632. The stock has a market cap of $240.87 billion, a P/E ratio of 14.94, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34. Merck &amp; Co., Inc. has a 12-month low of $73.31 and a 12-month high of $105.07. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a 50 day simple moving average of $85.43 and a 200 day simple moving average of $82.43. </p><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.36 by $0.22. Merck &amp; Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. During the same quarter last year, the company earned $1.57 EPS. The firm's revenue was up 3.7% compared to the same quarter last year.  Merck &amp; Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. On average, research analysts forecast that  Merck &amp; Co., Inc. will post 9.01 EPS for the current fiscal year. </p><h2>Insider Buying and Selling at Merck &amp; Co., Inc.</h2><ul><li>5 Healthcare Plays Powering the Sector’s Big Comeback</li></ul><p>In related news, EVP David Michael Williams sold 8,614 shares of the firm's stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president directly owned 24,578 shares of the company's stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own  0.13% of the company's stock. </p><h2>Institutional Investors Weigh In On Merck &amp; Co., Inc.</h2><p>Several institutional investors have recently bought and sold shares of the business. Darwin Wealth Management LLC increased its holdings in shares of  Merck &amp; Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after acquiring an additional 216 shares during the last quarter.  Legend Financial Advisors Inc. purchased a new stake in shares of  Merck &amp; Co., Inc. in the second quarter worth approximately $25,000.  Kilter Group LLC bought a new stake in shares of  Merck &amp; Co., Inc. in the 2nd quarter valued at approximately $27,000.  Barnes Dennig Private Wealth Management LLC raised its position in shares of  Merck &amp; Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after purchasing an additional 266 shares during the period.  Finally, Bare Financial Services Inc boosted its position in shares of  Merck &amp; Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company's stock valued at $29,000 after acquiring an additional 125 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Merck &amp; Co., Inc.</h2> (Get Free Report)<p>Merck &amp; Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.</p><h2>Read More</h2><ul><li>Five stocks we like better than Merck &amp; Co., Inc.</li><li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li><li>Stellantis Makes a High-Stakes Bet on Jeep</li><li>Stock Average Calculator      </li><li>Nuclear Energy Earnings: Which Names Won and Lost in Q3</li><li>What is a support level?</li><li>Alphabet: Buffett's Bet on Its Next Phase of Growth</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p><p>While Merck &amp; Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Deutsche Bank Aktiengesellschaft raised its price target for Merck & Co., Inc. from $110.00 to $111.00, maintaining a "hold" rating. This suggests a potential upside of 14.38% from the current price. The stock has mixed ratings from various analysts, with a consensus "hold" rating and an average target price of $104.88. Merck's recent earnings exceeded expectations, with a reported EPS of $2.58 for the quarter.</p>

Deutsche Bank Aktiengesellschaft Raises Merck & Co., Inc. (NYSE:MRK) Price Target to $111.00